Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 1812.1, up 1.6% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.18% on the day, quoting at 25360.65. The Sensex is at 83104.96, down 0.16%. Glenmark Pharmaceuticals Ltd has gained around 14.34% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 3.4% in last one month and is currently quoting at 22204.25, up 0.79% on the day. The volume in the stock stood at 3.99 lakh shares today, compared to the daily average of 10.37 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1821.7, up 1.76% on the day. Glenmark Pharmaceuticals Ltd is up 35.42% in last one year as compared to a 4.26% jump in NIFTY and a 9.41% jump in the Nifty Pharma index.The PE of the stock is 28.84 based on TTM earnings ending March 25.Powered by Capital Market - Live

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 1773.3, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.22% on the day, quoting at 25484.65. The Sensex is at 83437.68, down 0.31%. Glenmark Pharmaceuticals Ltd has gained around 17.13% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 3.58% in last one month and is currently quoting at 22041.25, up 0.35% on the day. The volume in the stock stood at 2.49 lakh shares today, compared to the daily average of 11.89 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1779.6, up 0.78% on the day. Glenmark Pharmaceuticals Ltd is up 38.34% in last one year as compared to a 4.93% jump in NIFTY and a 11.06% jump in the Nifty Pharma index.The PE of the stock is 28.38 based on TTM earnings ending March 25.Powered by Capital Market - Live

Glenmark Pharmaceuticals (Glenmark) launched TEVIMBRA' (tislelizumab) in India following the approval by Central Drugs Standard Control Organization (CDSCO). TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. It is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and esophageal squamous cell carcinoma (ESCC) as monotherapy. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio. NSCLC is the most common type of lung cancer, representing over 80% of all lung cancer cases. Similarly, ESCC is the most common histological subtype of esophageal cancer in India. TEVIMBRA caters to the needs of this significant patient population by offering a differentiated and proven treatment option for these cancers. TEVIMBRA is approved and marketed in multiple leading global markets including the United States, European Union, Australia and China. Designed to selectively bind to PD-1 receptors, TEVIMBRA restores T-cell function while minimizing off-target immune suppression and has demonstrated robust efficacy with a favorable safety profile across diverse solid tumor types in multiple pivotal Phase 3 studies and through a comprehensive global clinical development program.Powered by Capital Market - Live

The key domestic indices pared all gains and traded with minor losses in mid-morning trade, amid ongoing geopolitical tensions between Israel and Iran. Market direction remains sensitive to geopolitical developments. Investors will closely monitor crude oil prices, developments from the G7 summit and the outcome of the upcoming U.S. Federal Reserve meeting. The Nifty slipped below the 24,850 mark. Media shares witnessed selling pressure for the second consecutive trading session. At 11:25 IST, the barometer index, the S&P BSE Sensex declined 195.99 points or 0.24% to 81,390.04. The Nifty 50 index declined 46.05 points or 0.19% to 24,807.80. In the broader market, the S&P BSE Mid-Cap index fell 0.27% and the S&P BSE Small-Cap index shed 0.13%. The market breadth was negative. On the BSE, 1,634 shares rose and 2,046 shares fell. A total of 270 shares were unchanged. IPO Update: The initial public offer (IPO) of Arisinfra Solutions received bids for 10,08,216 shares as against 1,30,84,656 shares on offer, according to stock exchange data at 11:24 IST on Wednesday (18 June 2025). The issue was subscribed 0.08 times. The issue opened for bidding on Wednesday (18 June 2025) and it will close on Friday (20 June 2025). The price band of the IPO is fixed between Rs 210 and 222 per share. An investor can bid for a minimum of 67 equity shares and in multiples thereof. Buzzing Index: The Nifty Media index fell 0.83% to 1,709.05. The index declined 1.55% for the two consecutive trading sessions. Dish TV India (down 2.05%), Saregama India (down 1.69%), D B Corp (down 1.38%), Zee Entertainment Enterprises (down 1.31%), Sun TV Network (down 0.89%), Tips Music (down 0.67%), Hathway Cable & Datacom (down 0.47%) and Network 18 Media & Investments (down 0.32%) declined. Stocks in Spotlight: Glenmark Pharmaceuticals rose 0.26%. The company announced that its manufacturing facility in Monroe, North Carolina, USA, has received a Form 483 with five procedural observations from the United States Food and Drug Administration (USFDA). Polycab India shed 0.32%. The company said that it has executed a contract worth Rs 6,447.54 crore with Bharat Sanchar Nigam (BSNL) to act as the project implementation agency (PIA) for the BharatNet project in Karnataka, Goa, and Puducherry. Global Markets: Markets in Asia traded in a mixed fashion on Wednesday, as escalating tensions between Israel and Iran weigh on investor sentiment. Adding fuel to fire, U.S. President Donald Trump is mulling a military strike on Iran, while demanding the country's leader Ayatollah Ali Khamenei 'surrender,' media reports stated. Japan exports in May declined 1.7% year on year, which is lower than the decline of 3.8% that was widely anticipated by the markets. The data comes a day after the Bank of Japan highlighted in its monetary policy statement that the country's growth was likely to 'moderate' on the back of factors like trade, which would lead to a slowdown in overseas economies and a decline in domestic corporate profits. On the Wall Street, all three major averages ended the trading day lower. The Dow Jones Industrial Average lost 299.29 points, or 0.70%, to close at 42,215.80. The S&P 500 shed 0.84% to end at 5,982.72, while the Nasdaq Composite fell 0.91% and settled at 19,521.09. The key indices ended lower ahead of the US Federal Reserve's rate decision, which is due Wednesday afternoon. The U.S. central bank is widely expected to hold rates steady, but investors will be keeping a close eye on Fed Chair Jerome Powell's post-meeting comments. Traders are also watching for policymakers' forecast on rate policy, as the Federal Open Market Committee will be sharing members' 'dot plot' of rate expectations.Powered by Capital Market - Live

According to a regulatory filing by the company, the USFDA conducted a good manufacturing practices (GMP) inspection at the Monroe site from 9 June to 17 June 2025. Following the conclusion of the inspection, the USFDA has issued a Form 483 with five observations. Glenmark clarified that all the observations are procedural in nature and none pertain to data integrity. The company stated that it will work closely with the USFDA to address the observations and will submit its response within the stipulated timeline. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. On a consolidated basis, Glenmark Pharmaceuticals reported net profit of Rs 4.65 crore in Q4 March 2025 as against net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025. The counter shed 0.30% to Rs 1,648.80 on the BSE. Powered by Capital Market - Live

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 1631.4, up 0.98% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.38% on the day, quoting at 25199.55. The Sensex is at 82711.36, up 0.39%. Glenmark Pharmaceuticals Ltd has risen around 18.07% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has risen around 4.47% in last one month and is currently quoting at 21948, up 0.45% on the day. The volume in the stock stood at 3.64 lakh shares today, compared to the daily average of 9.49 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1637.3, up 1.11% on the day. Glenmark Pharmaceuticals Ltd is up 35.62% in last one year as compared to a 8.05% spurt in NIFTY and a 11.69% spurt in the Nifty Pharma index.The PE of the stock is 26.14 based on TTM earnings ending March 25.Powered by Capital Market - Live

Co-developed with global oncology leader BeOne Medicines, zanubrutinib will be marketed under the brand name Brukinsa. It is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for five types of B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenstr'm macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL). Globally, Brukinsa is approved in over 70 countries, backed by robust clinical evidence from pivotal trials such as Alpine, Aspen, and Sequoia. The drug has shown a strong safety profile, high response rates, and durable disease control. With one Indian diagnosed with blood cancer every five minutes and around 70,000 deaths annually, Brukinsa addresses a critical treatment gap. Its flexible dosing (once or twice daily) supports personalized care. In the Alpine study for relapsed/refractory CLL, Brukinsa reported significantly fewer serious cardiac events (1.9% vs 7.7%) and lower treatment discontinuation (0.3% vs 4.3%) compared to ibrutinib. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. On a consolidated basis, Glenmark Pharmaceuticals reported net profit of Rs 4.65 crore in Q4 March 2025 as against net loss of Rs 1218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025. Powered by Capital Market - Live

Glenmark Pharmaceuticals has announced the upcoming launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI). Zanubrutinib will be marketed in India under the brand name BRUKINSA', an innovative therapy developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. BRUKINSA is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenstr'm macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL). Globally, BRUKINSA is approved in more than 70 countries, supported by compelling clinical evidence from pivotal trials including ALPINE, ASPEN, and SEQUOIA. This extensive clinical program underscores BRUKINSA's proven efficacy, strong safety profile, and broad therapeutic value. The introduction of BRUKINSA brings an innovative treatment option at a time when India continues to face a significant burden from serious and difficult-to-treat haematological malignancies. According to various sources, someone in India is diagnosed with blood cancer every five minutes, and an estimated 70,000 people die from the disease each year. BRUKINSA addresses a critical unmet need with its differentiated pharmacological profile, demonstrating high response rates and durable disease control across multiple B-cell malignancies as shown in pivotal clinical trials. BRUKINSA's flexible dosing regimen (once or twice daily) supports personalized care.1 In the head-to-head ALPINE study in relapsed/refractory chronic lymphocytic leukemia, BRUKINSA demonstrated a lower rate of serious cardiac events (1.9% vs. 7.7%) and fewer treatment discontinuations due to cardiac issues (0.3% vs. 4.3%) compared with ibrutinib.Powered by Capital Market - Live

Glenmark Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 23 May 2025, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Glenmark Pharmaceuticals reported to Rs 4.65 crore in the quarter ended March 2025 as against net loss of Rs 1218.28 crore during the previous quarter ended March 2024. Sales rose 6.77% to Rs 3220.13 crore in the quarter ended March 2025 as against Rs 3016.01 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 1047.10 crore in the year ended March 2025 as against net loss of Rs 1501.67 crore during the previous year ended March 2024. Sales rose 12.98% to Rs 13145.84 crore in the year ended March 2025 as against Rs 11635.46 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales3220.133016.01 7 13145.8411635.46 13 OPM %17.4216.72 -17.8910.27 - PBDT506.001128.95 -55 2258.041519.36 49 PBT380.79977.61 -61 1772.03937.45 89 NP4.65-1218.28 LP 1047.10-1501.67 LP Powered by Capital Market - Live